https://pubmed.ncbi.nlm.nih.gov/31629805/
Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 ...
Ruxolitinib, a selective inhibitor of Janus kinase 1 and Janus kinase 2, potently suppresses cytokine signaling involved in AD pathogenesis.